NxThera closes $20M Series C round

NxThera puts a bow on a $20 million Series C round for its Rezūm prostate device. NxThera said it closed a $20 million Series C round that topped its initial $18 million target. Maple Grove, Minn.-based NxThera won CE Mark approval in the European Union last August for its Rezūm prostate device, which uses steam to reduce the size of the prostate to relieve urinary symptoms from benign prostate hyperplasia. NxThera Inc.News Well, Funding Roundup, Prostateread more
Source: Mass Device - Category: Medical Equipment Authors: Source Type: news